• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Response to Dual Crizotinib and Osimertinib Treatment in a Lung Cancer Patient with MET Amplification Detected by Liquid Biopsy Who Acquired Secondary Resistance to EGFR Tyrosine Kinase Inhibition.

作者信息

Deng Lei, Kiedrowski Lesli A, Ravera Elizabeth, Cheng Haiying, Halmos Balazs

机构信息

Department of Medicine, Jacobi Medical Center/Albert Einstein College of Medicine, Bronx, New York.

Guardant Health, Inc., Redwood City, California.

出版信息

J Thorac Oncol. 2018 Sep;13(9):e169-e172. doi: 10.1016/j.jtho.2018.04.007.

DOI:10.1016/j.jtho.2018.04.007
PMID:30166014
Abstract
摘要

相似文献

1
Response to Dual Crizotinib and Osimertinib Treatment in a Lung Cancer Patient with MET Amplification Detected by Liquid Biopsy Who Acquired Secondary Resistance to EGFR Tyrosine Kinase Inhibition.液体活检检测到MET扩增且对EGFR酪氨酸激酶抑制产生继发性耐药的肺癌患者对克唑替尼和奥希替尼联合治疗的反应
J Thorac Oncol. 2018 Sep;13(9):e169-e172. doi: 10.1016/j.jtho.2018.04.007.
2
MET amplification results in heterogeneous responses to osimertinib in EGFR-mutant lung cancer treated with erlotinib.MET 扩增导致接受厄洛替尼治疗的 EGFR 突变型肺癌对奥希替尼的异质性反应。
Cancer Sci. 2020 Oct;111(10):3813-3823. doi: 10.1111/cas.14593. Epub 2020 Sep 1.
3
Clinical analysis by next-generation sequencing for NSCLC patients with MET amplification resistant to osimertinib.MET 扩增型非小细胞肺癌患者奥希替尼耐药的下一代测序临床分析。
Lung Cancer. 2018 Apr;118:105-110. doi: 10.1016/j.lungcan.2018.02.007. Epub 2018 Feb 13.
4
Combining EGFR and MET Inhibition With Crizotinib in EGFR-mutated Lung Adenocarcinoma Harboring MET Amplification: A Brief Report.在携带MET扩增的EGFR突变肺腺癌中联合使用克唑替尼抑制EGFR和MET：简要报告
Clin Lung Cancer. 2020 Nov;21(6):e601-e606. doi: 10.1016/j.cllc.2020.05.015. Epub 2020 May 23.
5
High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression.在一名奥希替尼进展后对克唑替尼治疗有症状反应的患者中，高MET扩增水平作为对奥希替尼（AZD9291）的耐药机制。
Lung Cancer. 2016 Aug;98:59-61. doi: 10.1016/j.lungcan.2016.05.015. Epub 2016 May 25.
6
GOPC-ROS1 Rearrangement as an Acquired Resistance Mechanism to Osimertinib and Responding to Crizotinib Combined Treatments in Lung Adenocarcinoma.GOPC-ROS1重排作为肺腺癌对奥希替尼获得性耐药机制及对克唑替尼联合治疗敏感的机制
J Thorac Oncol. 2018 Jul;13(7):e114-e116. doi: 10.1016/j.jtho.2018.02.005.
7
Novel SPECC1L-MET Fusion Detected in Circulating Tumor DNA in a Patient with Lung Adenocarcinoma following Treatment with Erlotinib and Osimertinib.在一名接受厄洛替尼和奥希替尼治疗的肺腺癌患者的循环肿瘤DNA中检测到新型SPECC1L-MET融合基因。
J Thorac Oncol. 2019 Feb;14(2):e27-e29. doi: 10.1016/j.jtho.2018.10.160.
8
Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment.基因扩增和蛋白过度激活是肺癌治疗中对第一代和第三代 EGFR 抑制剂产生耐药的机制。
Cancer Lett. 2016 Oct 1;380(2):494-504. doi: 10.1016/j.canlet.2016.07.021. Epub 2016 Jul 19.
9
Crizotinib plus erlotinib overcomes osimertinib resistance in a seriously-ill non-small cell lung cancer patient with acquired MET amplification.克唑替尼联合厄洛替尼克服了一名患有获得性MET扩增的重症非小细胞肺癌患者对奥希替尼的耐药性。
Chin Med J (Engl). 2020 Nov 12;134(3):373-374. doi: 10.1097/CM9.0000000000001184.
10
Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC).双重 MET 和 ERBB 抑制克服奥希替尼耐药晚期非小细胞肺癌（NSCLC）中的肿瘤内可塑性。
Ann Oncol. 2017 Oct 1;28(10):2451-2457. doi: 10.1093/annonc/mdx396.

引用本文的文献

1
Optimizing Osimertinib for NSCLC: Targeting Resistance and Exploring Combination Therapeutics.优化奥希替尼用于非小细胞肺癌的治疗：靶向耐药性并探索联合疗法。
Cancers (Basel). 2025 Jan 29;17(3):459. doi: 10.3390/cancers17030459.
2
Management of oligometastatic and oligoprogressive epidermal growth factor receptor mutated non-small cell lung cancer patients: state of the art of a combined approach.寡转移和寡进展性表皮生长因子受体突变的非小细胞肺癌患者的管理：联合治疗方法的现状
Explor Target Antitumor Ther. 2024;5(3):449-464. doi: 10.37349/etat.2024.00228. Epub 2024 May 17.
3
The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLC.
在转移性致癌基因驱动的非小细胞肺癌患者中，通过联合使用母代和MET酪氨酸激酶抑制剂治疗获得性MET耐药的疗效和安全性。
JTO Clin Res Rep. 2024 Jan 18;5(2):100637. doi: 10.1016/j.jtocrr.2024.100637. eCollection 2024 Feb.
4
Real-World Data on Combined EGFR-TKI and Crizotinib Treatment for Acquired and De Novo Amplification in Patients with Metastatic -Mutated NSCLC.针对转移性 - 突变型 NSCLC 患者获得性和从头扩增的 EGFR-TKI 和克唑替尼联合治疗的真实世界数据。
Int J Mol Sci. 2023 Aug 23;24(17):13077. doi: 10.3390/ijms241713077.
5
The Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Clinical Application of New Therapeutic Strategies.非小细胞肺癌对表皮生长因子受体酪氨酸激酶抑制剂的耐药性：从分子机制到新治疗策略的临床应用
Pharmaceutics. 2023 May 27;15(6):1604. doi: 10.3390/pharmaceutics15061604.
6
Osimertinib Resistance: Molecular Mechanisms and Emerging Treatment Options.奥希替尼耐药：分子机制与新出现的治疗选择
Cancers (Basel). 2023 Jan 30;15(3):841. doi: 10.3390/cancers15030841.
7
Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung Cancers.晚期 EGFR 突变型肺癌中一线奥希替尼获得性耐药的疾病结局分子标志物和机制。
J Thorac Oncol. 2023 Apr;18(4):463-475. doi: 10.1016/j.jtho.2022.11.022. Epub 2022 Dec 6.
8
Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance.奥希替尼耐药的表皮生长因子受体突变型非小细胞肺癌患者的治疗策略。
J Hematol Oncol. 2022 Dec 8;15(1):173. doi: 10.1186/s13045-022-01391-4.
9
MET Signaling Pathways, Resistance Mechanisms, and Opportunities for Target Therapies.MET 信号通路、耐药机制和靶向治疗机会。
Int J Mol Sci. 2022 Nov 11;23(22):13898. doi: 10.3390/ijms232213898.
10
Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Non-Small Cell Lung Cancer: TATTON.奥希替尼联合 savolitinib 克服表皮生长因子受体突变、MET 扩增的非小细胞肺癌获得性 MET 介导的耐药：TATTON。
Cancer Discov. 2023 Jan 9;13(1):98-113. doi: 10.1158/2159-8290.CD-22-0586.